Full metadata record
DC FieldValueLanguage
dc.contributorDepartment of Applied Biology and Chemical Technologyen_US
dc.contributor.advisorChow, M. C. Larry (ABCT)en_US
dc.creatorChow, Tsun Sing-
dc.identifier.urihttps://theses.lib.polyu.edu.hk/handle/200/10708-
dc.languageEnglishen_US
dc.publisherHong Kong Polytechnic Universityen_US
dc.rightsAll rights reserveden_US
dc.titleInteraction between Plasmodium falciparum chloroquine resistance transporter (PfCRT) and atpase: a mechanistic study on the mechanism of chloroquine resistance and its reversalen_US
dcterms.abstractPlasmodium falciparum chloroquine resistance transporter (PfCRT) is a transmembrane protein localized at the digestive vacuole (DV) membrane in Plasmodium falciparum (P. falciparum) parasite. Mutations in PfCRT correlated with chloroquine resistance (CQR) in malaria; among which K76T point mutation at the first transmembrane helix plays a critical role. The mutant PfCRT effluxes protonated chloroquine (CQ) from the DV of P.falciparum parasite in an ATP-dependent manner. However, PfCRT has no recognizable nucleotide binding domain to bind and hydrolyze ATP. Recently, PfCRT has been shown to physically and functionally interact with α and β subunits of F-ATPase when PfCRT was overexpressed in Pichia pastoris (P. pastoris). Similar interaction occurred between PfCRT and V-ATPase subunit B in P.falciparum (PfV1B). The interacting site between PfCRT and F-/V-ATPase, however, is unknown. By understanding the interacting site, specific inhibitors may be designed to disrupt PfCRT-V-ATPase interaction in P.falciparum to modulate CQR for future therapeutic use. In this project, the N terminus (1-58), internal loop 4 (265-315) and C terminus (399-424) of PfCRT were proposed to be the interacting domains. These 3 parts of PfCRT have the largest soluble domains and therefore have the highest chance of interacting with other proteins. Peptides derived from these parts were tested for their ability to disrupt PfCRT-F-ATPase interaction in P. pastoris microsome. It was found that both N terminus and C terminus can inhibit disuccinimidyl suberate (DSS)-crosslinking of PfCRT-F-ATPase, [3H]-CQ uptake activity and oligomycin A-inhibitable ATPase activity, suggesting that they were involved in such interaction. Truncation and mutation of PfCRT N and C terminus peptides were used to map the interacting regions in detail. The interaction between PfCRT and F-/V-ATPase was studied using the following 4 assays. (1) Physical interaction between C terminus of PfCRT and PfV1B and (2) physical interaction between PfCRT N terminus (1-20) and PfV1B were studied using pulldown assays. The functional consequence of PfCRT was also measured using (3) [3H]-CQ uptake assay and (4) F1-ATPase activity assay. It was found that 3 separate regions of PfCRT can physically and functionally interact with F-/V-ATPase, namely residues 1-20 of N terminus (MKFASKKNNQKNSSKNDERY), residues 21-40 of N terminus (RELDNLVQEGNGSRLGGGSC) and residues 408-424 of C terminus (NEDSEGELTNVDSIITQ). Peptide derived from residues 408-424 of PfCRT C terminus showed the most promising effect on disruption of PfCRT-F-/V-ATPase interaction including inhibition on PfCRT CQ transport activity (51±5%), binding of PfCRT C terminus to PfV1B (74±7%) and binding of PfCRT N terminus (1-20) to PfV1B (52±4%). Such region also has a mild F1-ATPase stimulatory effect (20±3%). This region, therefore, has a potential to be developed as a peptide to modulate CQ resistance. The above mapping results suggested that V1B can interact with 3 sites of PfCRT (2 in N terminus and 1 in C terminus). Based on this, a model for how PfCRT-V-ATPase interaction can regulate CQ transport is proposed which has three stages, namely N1-, N3- and C-stage. In these 3 stages, residues 1-20, 21-40 and 408-424 of PfCRT was interacting with PfV1B, respectively. Interaction between PfCRT and V-ATPase is slightly different in each stage and the transition between stages might be responsible for the coupling of ATP hydrolysis in V-ATPase and CQ transport activity of PfCRT. PfCRT is in "resting", "inward-facing" and "outward-facing" conformation and V-ATPase is in "open", "tight" and "loose" conformation in these 3 stages, respectively. Such model could explain how PfCRT uses the 3 sites to bind to V-ATPase, changes the conformation of the latter, activates the ATPase activity and couples this to the conformational changes of PfCRT to transport CQ.en_US
dcterms.extentxviii, 177 pages : color illustrationsen_US
dcterms.isPartOfPolyU Electronic Thesesen_US
dcterms.issued2020en_US
dcterms.educationalLevelPh.D.en_US
dcterms.educationalLevelAll Doctorateen_US
dcterms.LCSHDrug resistanceen_US
dcterms.LCSHChloroquineen_US
dcterms.LCSHHong Kong Polytechnic University -- Dissertationsen_US
dcterms.accessRightsopen accessen_US

Files in This Item:
File Description SizeFormat 
5130.pdfFor All Users5.47 MBAdobe PDFView/Open


Copyright Undertaking

As a bona fide Library user, I declare that:

  1. I will abide by the rules and legal ordinances governing copyright regarding the use of the Database.
  2. I will use the Database for the purpose of my research or private study only and not for circulation or further reproduction or any other purpose.
  3. I agree to indemnify and hold the University harmless from and against any loss, damage, cost, liability or expenses arising from copyright infringement or unauthorized usage.

By downloading any item(s) listed above, you acknowledge that you have read and understood the copyright undertaking as stated above, and agree to be bound by all of its terms.

Show simple item record

Please use this identifier to cite or link to this item: https://theses.lib.polyu.edu.hk/handle/200/10708